Carbonic anhydrase 9 in clear cell renal cell carcinoma: A marker for diagnosis, prognosis and treatment

European Journal of Cancer

Volumn 46, Issue 18, 2010, Pages 3141-3148

  Tostain, Jacques ^a   Li, Guorong ^a   Gentil Perret, Anne ^a   Gigante, Marc ^a  

^a UNIVERSITÉ JEAN MONNET   (France)

Author keywords

Biomarkers; Carbonic anhydrase 9; Diagnosis; ELISA; Immunohistochemistry; Prognosis; Renal cancer; RT PCR; Treatment

Indexed keywords

ACETAZOLAMIDE; ALPHA INTERFERON; CA9 VACCINE; CANCER VACCINE; CARBON DIOXIDE; CARBONATE DEHYDRATASE IX; EPIDERMAL GROWTH FACTOR RECEPTOR; INDISULAM; INTERLEUKIN 2; MAMMALIAN TARGET OF RAPAMYCIN; MESSENGER RNA; MONOCLONAL ANTIBODY G250; SORAFENIB; UNCLASSIFIED DRUG; VON HIPPEL LINDAU PROTEIN;

ADJUVANT THERAPY; ANTINEOPLASTIC ACTIVITY; CANCER DIAGNOSIS; CANCER GROWTH; CANCER LOCALIZATION; CANCER SURVIVAL; CATALYSIS; CLINICAL TRIAL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MEGADOSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FOLLOW UP; GENE INACTIVATION; GENE OVEREXPRESSION; GENETIC TRANSFECTION; HUMAN; HYDRATION; HYPOXIA; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; LOW DRUG DOSE; NONHUMAN; PH MEASUREMENT; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SENSITIVITY AND SPECIFICITY; SINGLE DRUG DOSE; SURVIVAL TIME; TREATMENT RESPONSE; TUMOR CELL; TUMOR MICROENVIRONMENT;

EID: 78649636616     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2010.07.020     Document Type: Article

References (63)

1. D.M. Parkin, F. Bray, J. Ferlay, and P. Pisani Global cancer statistics, 2002 CA Cancer J Clin 55 2005 74 108
2. J.S. Lam, J.T. Leppert, R.A. Figlin, and A.S. Belldegrun Role of molecular markers in the diagnosis and therapy of renal cell carcinoma Urology 66 2005 1 9
3. B.C. Leibovich, M.L. Blute, and J.C. Cheville Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma: a stratification tool for prospective clinical trials Cancer 97 2003 1663 1671
4. H.L. Kim, D. Seligson, and X. Liu Using tumor markers to predict the survival of patients with metastatic renal cell carcinoma J Urol 173 2005 1496 1501
5. E. Oosterwijk, D.J. Ruiter, and P.J. Hoedemaeker Monoclonal antibody G 250 recognizes a determinant present in renal-cell carcinoma and absent from normal kidney Int J Cancer 38 1986 489 494
6. J. Zavada, Z. Zavadova, and S. Pastorekova Expression of MaTu-MN protein in human tumor cultures and in clinical specimens Int J Cancer 54 1993 268 274
7. J. Pastorek, S. Pastorekova, and I. Callebaut Cloning and characterization of MN, a human tumor-associated protein with a domain homologous to carbonic anhydrase and a putative helix-loop-helix DNA binding segment Oncogene 9 1994 2877 2888
8. K. Grabmaier, J.L. Vissers, and M.C. De Weijert Molecular cloning and immunogenicity of renal cell carcinoma-associated antigen G250 Int J Cancer 85 2000 865 870
9. M. Zatovicova, O. Sedlakova, and E. Svastova Ectodomain shedding of the hypoxia-induced carbonic anhydrase IX is a metalloprotease-dependent process regulated by TACE/ADAM17 Br J Cancer 93 2005 1267 1276
10. B.C. Leibovich, Y. Sheinin, and C.M. Lohse Carbonic anhydrase IX is not an independent predictor of outcome for patients with clear cell renal cell carcinoma J Clin Oncol 25 2007 4757 4764
11. C.C. Wykoff, N.J. Beasley, and P.H. Watson Hypoxia-inducible expression of tumor-associated carbonic anhydrases Cancer Res 60 2000 7075 7083
12. L.J. McCawley, and L.M. Matrisian Matrix metalloproteinases: multifunctional contributors to tumor progression Mol Med Today 6 2000 149 156
13. S.J. Mandriota, K.J. Turner, and D.R. Davies HIF activation identifies early lesions in VHL kidneys: evidence for site-specific tumor suppressor function in the nephron Cancer Cell 1 2002 459 468
14. S.V. Ivanov, I. Kuzmin, and M.H. Wei Down-regulation of transmembrane carbonic anhydrases in renal cell carcinoma cell lines by wild-type von Hippel-Lindau transgenes Proc Natl Acad Sci USA 95 1998 12596 12601
15. J.J. Patard, P. Fergelot, and P.I. Karakiewicz Low CAIX expression and absence of VHL gene mutation are associated with tumor aggressiveness and poor survival of clear cell renal cell carcinoma Int J Cancer 123 2008 395 400
16. M. Ivan, K. Kondo, and H. Yang HIF alpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing Science 292 2001 464 468
17. K. Grabmaier, M.C. AdW, G.W. Verhaegh, J.A. Schalken, and E. Oosterwijk Strict regulation of CAIX(G250/MN) by HIF-1alpha in clear cell renal cell carcinoma Oncogene 23 2004 5624 5631
18. M.M. Baldewijns, V.L. Thijssen, and G.G. Van den Eynden High-grade clear cell renal cell carcinoma has a higher angiogenic activity than low-grade renal cell carcinoma based on histomorphological quantification and qRT-PCR mRNA expression profile Br J Cancer 96 2007 1888 1895
19. G. Li, K. Passebosc-Faure, and C. Lambert The expression of G250/mn/CA9 antigen by flow cytometry: its possible implication for detection of micrometastatic renal cancer cells Clin Cancer Res 7 2001 89 92
20. S.Y. Liao, O.N. Aurelio, K. Jan, J. Zavada, and E.J. Stanbridge Identification of the MN/CA9 protein as a reliable diagnostic biomarker of clear cell carcinoma of the kidney Cancer Res 57 1997 2827 2831
21. Y. Li, H. Wang, and E. Oosterwijk Antibody-specific detection of CAIX in breast and prostate cancers Biochem Biophys Res Commun 386 2009 488 492
22. M.H. Bui, D. Seligson, and K.R. Han Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy Clin Cancer Res 9 2003 802 811
23. J. Sandlund, E. Oosterwijk, and K. Grankvist Prognostic impact of carbonic anhydrase IX expression in human renal cell carcinoma BJU Int 100 2007 556 560 (Pubitemid 47205465)
24. S. Ivanov, S.Y. Liao, and A. Ivanova Expression of hypoxia-inducible cell-surface transmembrane carbonic anhydrases in human cancer Am J Pathol 158 2001 905 919
25. Y. Murakami, K. Kanda, M. Tsuji, H. Kanayama, and S. Kagawa MN/CA9 gene expression as a potential biomarker in renal cell carcinoma BJU Int 83 1999 743 747
26. J. Zavada, Z. Zavadova, M. Zat'ovicova, L. Hyrsl, and I. Kawaciuk Soluble form of carbonic anhydrase IX (CA IX) in the serum and urine of renal carcinoma patients Br J Cancer 89 2003 1067 1071
27. Li G, Feng G, Gentil-Perret A, Genin C, Tostain J. Serum carbonic anhydrase 9 level is associated with postoperative recurrence of conventional renal cell cancer. J Urol 2008;180:510-3 [discussion 13-4].
28. P. Hulick, M. Zimmer, and V. Margulis Blood levels of carbonic anhydrase 9 correlate with clear cell carcinoma activity Clin Proteom 5 2009 34 45
29. G.X. Zhou, J. Ireland, P. Rayman, J. Finke, and M. Zhou Quantification of carbonic anhydrase IX expression in serum and tissue of renal cell carcinoma patients using enzyme-linked immunosorbent assay: prognostic and diagnostic potentials Urology 75 2010 257 261
30. G. Li, M. Cuilleron, and A. Gentil-Perret Rapid and sensitive detection of messenger RNA expression for molecular differential diagnosis of renal cell carcinoma Clin Cancer Res 9 2003 6441 6446
31. Y. Nakagawa, H. Uemura, and Y. Hirao Radiation hybrid mapping of the human MN/CA9 locus to chromosome band 9p12-p13 Genomics 53 1998 118 119
32. M. de Martino, T. Klatte, and D.B. Seligson CA9 gene: single nucleotide polymorphism predicts metastatic renal cell carcinoma prognosis J Urol 182 2009 728 734
33. Y. Neuzillet, E. Lechevallier, M. Andre, L. Daniel, and C. Coulange Accuracy and clinical role of fine needle percutaneous biopsy with computerized tomography guidance of small (less than 4.0 cm) renal masses J Urol 171 2004 1802 1805
34. E. Lechevallier, M. Andre, and D. Barriol Fine-needle percutaneous biopsy of renal masses with helical CT guidance Radiology 216 2000 506 510 (Pubitemid 30599874)
35. J.S. Wolf Jr. Evaluation and management of solid and cystic renal masses J Urol 159 1998 1120 1133
36. G. Li, M. Cuilleron, and M. Cottier The use of MN/CA9 gene expression in identifying malignant solid renal tumors Eur Urol 49 2006 401 405
37. H.K. Jensen, M. Nordsmark, F. Donskov, N. Marcussen, and H. Von der Maase Immunohistochemical expression of carbonic anhydrase IX assessed over time and during treatment in renal cell carcinoma BJU Int 101 Suppl. 4 2008 41 44
38. C.R. Divgi, N. Pandit-Taskar, and A.A. Jungbluth Preoperative characterisation of clear-cell renal carcinoma using iodine-124-labelled antibody chimeric G250 (124I-cG250) and PET in patients with renal masses: a phase I trial Lancet Oncol 8 2007 304 310
39. Tostain J, Li G. CA9 as a predictive marker of response to therapies of clear cell renal cell carcinoma. Oral presentation. In: Rein AplRslTd, editor. 3rd A.R.Tu.R Symposium 2009, Chantilly (France), 2009.
40. Li G, Billal I, Gentil-Perret A, et al. CA9 as a molecular marker for differential diagnosis of cystic renal tumors. Urol Oncol 2010, in press.
41. N.B. Phuoc, H. Ehara, and T. Gotoh Prognostic value of the co-expression of carbonic anhydrase IX and vascular endothelial growth factor in patients with clear cell renal cell carcinoma Oncol Rep 20 2008 525 530
42. S.M. Gilbert, J.M. Whitson, and M. Mansukhani Detection of carbonic anhydrase-9 gene expression in peripheral blood cells predicts risk of disease recurrence in patients with renal cortical tumors Urology 67 2006 942 945
43. M. Atkins, M. Regan, and D. McDermott Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer Clin Cancer Res 11 2005 3714 3721
44. Brouwers AH, Boerman OC, Oyen WJ. In vivo molecular prediction of carbonic anhydrase IX-G250MN expression on immunotherapy outcome in renal cancer. Clin Cancer Res 2005;11:8886 [author reply 86].
45. D. Cho, S. Signoretti, and S. Dabora Potential histologic and molecular predictors of response to temsirolimus in patients with advanced renal cell carcinoma Clin Genitourin Cancer 5 2007 379 385
46. S. Signoretti, M. Regan, and M. Atkins Carbonic anhydrase IX as a predictive biomarker of response to kidney cancer therapy BJU Int 101 Suppl. 4 2008 31 35
47. Y. Wang, X.Y. Wang, J.R. Subjeck, and H.L. Kim Carbonic anhydrase IX has chaperone-like functions and is an immunoadjuvant Mol Cancer Ther 7 2008 3867 3877
48. J. Zavada, Z. Zavadova, and J. Pastorek Human tumour-associated cell adhesion protein MN/CA IX: identification of M75 epitope and of the region mediating cell adhesion Br J Cancer 82 2000 1808 1813
49. E. Svastova, N. Zilka, and M. Zat'ovicova Carbonic anhydrase IX reduces E-cadherin-mediated adhesion of MDCK cells via interaction with beta-catenin Exp Cell Res 290 2003 332 345
50. A. Franovic, I. Robert, and K. Smith Multiple acquired renal carcinoma tumor capabilities abolished upon silencing of ADAM17 Cancer Res 66 2006 8083 8090
51. A. Franovic, L. Gunaratnam, and K. Smith Translational up-regulation of the EGFR by tumor hypoxia provides a nonmutational explanation for its overexpression in human cancer Proc Natl Acad Sci USA 104 2007 13092 13097
52. T. Dorai, I.S. Sawczuk, J. Pastorek, P.H. Wiernik, and J.P. Dutcher The role of carbonic anhydrase IX overexpression in kidney cancer Eur J Cancer 41 2005 2935 2947
53. C.T. Supuran Development of small molecule carbonic anhydrase IX inhibitors BJU Int 101 Suppl. 4 2008 39 40
54. E. Svastova, A. Hulikova, and M. Rafajova Hypoxia activates the capacity of tumor-associated carbonic anhydrase IX to acidify extracellular pH FEBS Lett 577 2004 439 445
55. J.L. Vissers, I.J. De Vries, and M.W. Schreurs The renal cell carcinoma-associated antigen G250 encodes a human leukocyte antigen (HLA)-A2.1-restricted epitope recognized by cytotoxic T lymphocytes Cancer Res 59 1999 5554 5559
56. H. Uemura, K. Fujimoto, and M. Tanaka A phase I trial of vaccination of CA9-derived peptides for HLA-A24-positive patients with cytokine-refractory metastatic renal cell carcinoma Clin Cancer Res 12 2006 1768 1775
57. Z. Su, J. Dannull, and A. Heiser Immunological and clinical responses in metastatic renal cancer patients vaccinated with tumor RNA-transfected dendritic cells Cancer Res 63 2003 2127 2133
58. I. Bleumer, A. Knuth, and E. Oosterwijk A phase II trial of chimeric monoclonal antibody G250 for advanced renal cell carcinoma patients Br J Cancer 90 2004 985 990
59. I. Bleumer, E. Oosterwijk, and J.C. Oosterwijk-Wakka A clinical trial with chimeric monoclonal antibody WX-G250 and low dose interleukin-2 pulsing scheme for advanced renal cell carcinoma J Urol 175 2006 57 62
60. C.H. Lamers, S. Sleijfer, and A.G. Vulto Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience J Clin Oncol 24 2006 e20 e22
61. C.R. Divgi, N.H. Bander, and A.M. Scott Phase I/II radioimmunotherapy trial with iodine-131-labeled monoclonal antibody G250 in metastatic renal cell carcinoma Clin Cancer Res 4 1998 2729 2739
62. 131I- labeled chimeric monoclonal antibody G250 Clin Cancer Res 5 1999 3268s 3274s
63. 131I-cG250 in patients with metastasized clear cell renal cell carcinoma J Clin Oncol 23 2005 6540 6548